DBV Technologies | DBVT - Loan Capital


DBV Technologies reported $0 in Loan Capital for its fiscal quarter ending in March of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
DBV Technologies USD 0 0 Mar/2025
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Galectin Therapeutics USD 93.42M 9.08M Jun/2024
Halozyme Therapeutics USD 1.94B 206.73M Mar/2026
Incyte USD 29.41M 785K Mar/2026
Insmed USD 542.22M 1.25M Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
United Therapeutics USD 100M 100M Jun/2024